# Boston Scientific to acquire Augmenix for $500M

Boston Scientific has entered a definitive agreement to acquire Augmenix, developer of the SpaceOAR System for prostate cancer radiotherapy, for an upfront cash payment of $500 million plus up to $100 million in sales-based milestones.

- Type: Acquisition
- Announced: 2018-09-06
- Where: United States
- Value: $500.0M
- Status: announced
- Products: SpaceOAR System (hydrogel therapy for prostate cancer radiotherapy)
- Sectors: [Medical Devices](https://endata.com/sectors/medical-devices.md)

## Companies

- [Boston Scientific](https://endata.com/companies/15966.md) (acquirer)
- [Augmenix](https://endata.com/companies/34155.md) (target)

## Sources

- [news.bostonscientific.com](https://news.bostonscientific.com/2018-09-06-Boston-Scientific-Announces-Agreement-To-Acquire-Augmenix-Inc), 2018-09-06: "The acquisition furthers our category leadership strategy in urology and the SpaceOAR hydrogel is a crucial addition to our growing prostate health treatment portfolio."
- [massdevice.com](https://www.massdevice.com/boston-scientific-closes-600m-augmenix-buyout/), 2018-10-17: "This close marks the third completed acquisition in 2018 for the company’s urology & pelvic health portfolio, further building upon our substantial momentum in this category."

---
Data from Endata (https://endata.com/). Announcements are summarized from public sources and may be incomplete; check the linked originals.